Core Viewpoint - The stock of Meihai Medical (301363) has shown a slight decline in price, with significant net outflows from major funds, indicating potential investor concerns about the company's performance and market conditions [1][2]. Group 1: Stock Performance - As of November 26, 2025, Meihai Medical's stock closed at 20.89 yuan, down 0.29% with a turnover rate of 0.78% and a trading volume of 29,300 hands, resulting in a transaction amount of 61.61 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop on November 21, 2025, where it fell by 3.79% [2]. Group 2: Fund Flow Analysis - On November 26, 2025, the net outflow of major funds was 479.83 million yuan, accounting for 7.79% of the total transaction amount, while retail investors saw a net inflow of 106.12 million yuan, representing 1.72% of the total [1][2]. - The recent trend shows that major funds have been withdrawing, with a cumulative net outflow over the past five days [2]. Group 3: Financial Metrics and Industry Comparison - Meihai Medical's total market capitalization is 11.884 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) stands at 42.81, which is lower than the industry average of 54.59, while its price-to-book ratio (P/B) is 3.21, also below the industry average of 3.86 [3]. - The gross margin for Meihai Medical is 39.34%, significantly lower than the industry average of 51.22%, indicating potential challenges in cost management [3]. Group 4: Recent Institutional Ratings - In the last 90 days, 14 institutions have rated Meihai Medical, with 12 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, indicating potential upside from the current trading price [4].
股票行情快报：美好医疗（301363）11月26日主力资金净卖出479.83万元